Keywords : Pharmaceutical, pharmaceuticals report
- Product Pipeline Review - H2 2011” provides a detailed overview on the Concert Pharmaceuticals, Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Concert Pharmaceuticals, Inc.’s corporate web...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Product Pipeline Review - H2 2011” provides a detailed overview on the Concert Pharmaceuticals, Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Concert Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Concert Pharmaceuticals, Inc. and market -specific third party sources, put together by Global Industries Direct’s team.
Scope of the Research
- Concert Pharmaceuticals, Inc. - Brief Concert Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Concert Pharmaceuticals, Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Concert Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Concert Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate Concert Pharmaceuticals, Inc.’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Concert Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Concert Pharmaceuticals, Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Concert Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Concert Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Global Pharmaceutical Industry
Table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 4
Concert Pharmaceuticals, Inc. Snapshot 5
Concert Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Concert Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Concert Pharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Concert Pharmaceuticals, Inc. – Pipeline Products Glance 9
Concert Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Concert Pharmaceuticals, Inc.–Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Concert Pharmaceuticals, Inc. – Drug Profiles 12
C-10003 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
C-10068 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
C-10291 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
C-21191 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
C-21359 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CTP-298 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CTP-499 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Concert Pharmaceuticals, Inc. – Pipeline Analysis 22
Concert Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 22
Concert Pharmaceuticals, Inc. - Pipeline Products By Target 24
Concert Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 25
Concert Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 26
Concert Pharmaceuticals, Inc. – Recent Pipeline Updates 27
Concert Pharmaceuticals, Inc. - Dormant Projects 28
Concert Pharmaceuticals, Inc. - Discontinued Pipeline Products 29
Discontinued Pipeline Product Profiles 29
CTP 518 29
Concert Pharmaceuticals, Inc. – Operations and Subsidiaries 30
Head Office 30
Recent Developments 31
March 31, 2010: Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347 31
March 29, 2011: Concert Initiates Phase I Clinical Study Of CTP-499 In Chronic Kidney Disease 31
October 27, 2008: Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential For Once Daily Dosing Of November el Oxazolidinone Antibiotic, C-20081 32
September 25, 2008: Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial 32
September 25, 2008: Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration Of CTP-347 And Tamoxifen 33
June 20, 2011: Concert Announces Milestone Achievement In GlaxoSmithKline Collaboration 34
June 20, 2011: Concert Pharmaceuticals Announces Advancement Of C-21191 For Spasticity 34
June 20, 2011: Concert Pharmaceuticals Announces Advancement Of CTP-499 In Kidney Disease 35
October 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting 36
October 19, 2011: Concert Pharmaceuticals To Present Data On Deuterium-Containing GABAA Modulators At Neuroscience 2011 36
March 16, 2009: Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347 37
November 10, 2009: Concert Pharmaceuticals Initiates Phase 1b Clinical Trial Of CTP-518, Protease Inhibitor For Treatment Of HIV 37
November 09, 2009: Concert Pharmaceuticals Initiates Phase Ib Clinical Trial Of CTP-518 For The Treatment Of HIV Infections 38
May 02, 2011: Concert Pharmaceuticals Presents Preclinical Data On C-10068 At Antiepileptic Drug Trials XI Conference 39
Financial Deals Landscape 40
Concert Pharmaceuticals, Inc., Merger and Acquisition Deal Summary 40
Concert Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 41
Venture Financing 41
Concert Pharmaceuticals Secures US$ 37 Mln In Series C Financing 41
Concert Pharmaceuticals Secures US$ 48.5 Mln In Series B Financing 44
Concert Pharmaceuticals Secures US$ 10 Mln In Series A Financing 46
Partnerships 48
GlaxoSmithKline Concludes a New Deal With Concert Pharmaceuticals 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 51
Contact Us 51
Disclaimer 51
List of Tables
Concert Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011 7
Concert Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011 8
Concert Pharmaceuticals, Inc. - Phase I, H2 2011 9
Concert Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011 23
Concert Pharmaceuticals, Inc. - Pipeline By Target, H2 2011 24
Concert Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011 25
Concert Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011 26
Concert Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011 27
Concert Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010 28
Concert Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010 29
Concert Pharmaceuticals, Inc., Merger and Acquisition Deal Summary 40
Concert Pharmaceuticals Secures US$ 37 Mln In Series C Financing 41
Concert Pharmaceuticals Secures US$ 48.5 Mln In Series B Financing 44
Concert Pharmaceuticals Secures US$ 10 Mln In Series A Financing 46
GlaxoSmithKline Concludes a New Deal With Concert Pharmaceuticals 48
List of Figures
Concert Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011 7
Concert Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011 8
Concert Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011 22
Concert Pharmaceuticals, Inc. - Pipeline By Target, H2 2011 24
